Sequana Medical Appoints Two Additional Experts as Heart Failure Scientific Advisors
Dr. Felker and Dr. Udelson join current advisors to support the development of alfapump® DSR for the management of fluid overload in patients with heart failure
GHENT, Belgium, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces the appointments of Dr. Michael Felker and Dr. James Udelson as new Heart Failure Scientific Advisors.
They join current advisors Dr. Javed Butler, Dr. Maria Rosa Costanzo, Dr. Wilson Tang and Dr. Jeffrey Testani as Heart Failure Scientific Advisors to Sequana Medical. The Sequana Medical management team is working closely with its advisors on the development of alfapump DSR (Direct Sodium Removal).
Built on its proven alfapump platform, alfapump DSR is Sequana Medical’s breakthrough approach for the management of fluid overload in patients suffering from heart failure. Pre-clinical and clinical proof-of-concept data from a first-in-human single dose DSR study demonstrated that single dose DSR therapy was safe and well-tolerated and the positive results were published in the high impact peer-reviewed cardiovascular journal, Circulation. Sequana Medical is currently conducting RED DESERT, a repeated dose alfapump DSR study in diuretic-resistant heart failure patients and expects to report interim results in Q4 2020 and top-line results in H1 2021.
“There is an urgent medical need for new treatment options for diuretic-resistant heart failure patients and I look forward to working with the Sequana Medical team and advisors to support the ongoing development of alfapump DSR to address this need,” said Dr. Felker. “The alfapump DSR has the potential to offer a much-needed alternative treatment option for this underserved patient population, who are so challenging to treat with current therapies. Sequana Medical has made good progress with the alfapump DSR with impressive pre-clinical and early clinical data, and I look forward to playing a part in the ongoing development of this exciting product,” added Dr. Udelson.
“I am delighted that Dr. Felker and Dr. Udelson have agreed to join our group of Heart Failure Scientific Advisors – they are renowned experts in the field and their knowledge and experience, alongside that of our existing advisors, will be invaluable as we work to bring alfapump DSR to this large patient group that has limited current options,” said Ian Crosbie, Chief Executive Officer of Sequana Medical. “The global heart failure market represents a tremendous opportunity for Sequana Medical and we look forward to providing an update on the interim results from our RED DESERT study later this year.”
About Dr. Felker
About Dr. Udelson
About Sequana Medical
In the U.S., the company's key growth market, the alfapump has been granted breakthrough device designation by the FDA. The North American pivotal study (POSEIDON) in recurrent and refractory ascites due to liver cirrhosis is currently underway, and is intended to support a commercial marketing application of the alfapump in the U.S. and Canada. In Europe, the alfapump is CE-marked for the management of refractory ascites due to liver cirrhosis and malignant ascites and is included in key clinical practice guidelines. Over 800 alfapump systems have been implanted to date. Building on its proven alfapump platform, Sequana Medical is developing the alfapump DSR, a breakthrough, proprietary approach to fluid overload due to heart failure. Clinical proof-of-concept was achieved in a first-in-human single dose DSR study and a repeated dose alfapump DSR study (RED DESERT) in heart failure patients is currently underway.
Sequana Medical is headquartered in Ghent, Belgium. For further information, please visit www.sequanamedical.com.
Important Regulatory Disclaimers
Smart City with a Social Conscience
AI Use Case